Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune clues in the blood may foretell heart trouble

NCT ID NCT07737470

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrillation within one year. The goal is to improve early diagnosis and risk assessment for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict heart complications in people with inflammatory diseases and point toward new treatment targets.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test any therapy. The findings may not apply to all patients or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults enrolled in the EACVI-INFLAME study with suspected or previously diagnosed inflammatory cardiovascular diseases (ICARDs) referred for cardiovascular magnetic resonance (CMR) and/or nuclear imaging, who provide informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient enrolled in EACVI-INFLAME study * The patient consents Exclusion Criteria: * Patients with a history of heart transplant * Patient unable to provide informed consent * Patient under complete or limited guardianship * Patient affected by pre-existing immunodeficiency, including HIV (not including immunosuppressive treatment)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA associated vasculitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome Behcet disease Giant Cell Arteritis granulomatosis with polyangiitis inflammatory disease juvenile idiopathic arthritis lupus erythematosus myocarditis myositis disease pericarditis rheumatoid arthritis Spondylarthritis spondyloarthropathy systemic sclerosis systemic-onset juvenile idiopathic arthritis Takayasu arteritis Tako-tsubo cardiomyopathy temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA associated vasculitis Antiphospholipid syndrome Behçet disease Giant cell arteritis Idiopathic inflammatory myopathies Inflammatory cardiomyopathies Inflammatory cardiovascular diseases Lupus Myocarditis Pericarditis Rheumatoid arthritis Spondyloarthritis Still disease Systemic sclerosis Takayasu arteritis Tako tsubo cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.